Cancer Research Institute, Inc.

The Leader in Immunotherapy

aka CRI   |   New York, NY   |  https://www.cancerresearch.org

Mission

SAVE MORE LIVES by fueling the discovery and development of powerful immunotherapies for all types of cancer.

Ruling year info

1953

CEO and Director of Scientific Affairs

Jill O'Donnell-Tormey Ph.D.

Main address

29 Broadway, Floor 4

New York, NY 10006 USA

Show more contact info

Formerly known as

New York Cancer Research Institute

EIN

13-1837442

NTEE code info

Cancer Research (H30)

Fund Raising and/or Fund Distribution (H12)

IRS filing requirement

This organization is required to file an IRS Form 990 or 990-EZ.

Sign in or create an account to view Form(s) 990 for 2019, 2018 and 2017.
Register now

Communication

Blog

Programs and results

What we aim to solve

SOURCE: Self-reported by organization

Decades of scientific research have confirmed that our own immune systems are able to see and eliminate cancer. Recent clinical trials have also demonstrated that immunotherapy--treatments that mobilize the immune system to fight cancer--can be an effective treatment for some patients. More scientific research is needed, however, to learn why some patients respond to treatment while others do not. More clinical trials are needed to test immunotherapy in more types of cancer as well as to find optimal combinations that have the greatest potential of benefiting patients. CRI is committed to driving the science of cancer immunology forward so that we will one day soon see a future immune to cancer.

Our programs

SOURCE: Self-reported by organization

What are the organization's current programs, how do they measure success, and who do the programs serve?

CRI Irvington Postdoctoral Fellowship Program

The CRI Irvington Postdoctoral Fellowship Program provides support to fund and train young immunologists and cancer immunologists at top universities and research centers around the world. Fellows receive up to $175,500 over three years to cover the cost of stipend or salary, insurance, and other research-related expenses, such as travel to conferences and meetings. Fellows work and continue their training under the guidance of a world-leading immunologist, who mentors the fellow and prepares him or her for a productive and successful career in cancer immunology.

Population(s) Served
Academics
People with diseases and illnesses

The Clinic and Laboratory Integration Program (CLIP) supports qualified scientists who are working to explore clinically relevant questions aimed at improving the effectiveness of cancer immunotherapies. The program funds basic, pre-clinical, and translational research that can be directly applied to optimizing cancer immunotherapy in the clinic. CLIP grants provide up to $200,000 over four years.

Population(s) Served
Academics
People with diseases and illnesses

The Clinical Accelerator is an actively managed venture philanthropy program designed to speed the development of cancer immunotherapies. The strategy facilitates research collaboration across leading biopharma companies and among 50 of the world’s top cancer researchers. The program aims to identify and kick-start development of next generation combination treatments using the most promising drugs from disparate companies.

Each philanthropic investment brings a new cancer treatment to patients, empowers academic researchers to work more closely with industry, and creates the potential for significant future returns on investment back to CRI to make the venture fund self-sustaining. Launched in mid-2012, the program has created partnerships with or is finalizing terms with more than 15 of the field’s top companies.

Four core resources empower the Clinical Accelerator:

*Coordinated Network of Researchers
*Nonprofit Venture Fund
*Clinical Trials Management
*Portfolio of BioPharma Partnerships

Population(s) Served
Academics
People with diseases and illnesses

These grants support research projects and public education and awareness initiatives for which, in most cases, donors have specifically raised funds.

Population(s) Served
Academics
People with diseases and illnesses

In addition to providing financial support to researchers and investigators, CRI also honors scientists and community leaders with achievement awards. These awards are presented at our annual dinner.

*William B. Coley Award for Distinguished Research in Basic and Tumor Immunology
CRI grants the Coley Award annually to one or more scientists whose discoveries in the fields of immunology or tumor immunology contribute to the advancement of immune system-based therapies for cancer. CRI established the award in 1975 in honor of Dr. William B. Coley, the acknowledged “Father of Cancer Immunotherapy,” whose daughter, Helen Coley Nauts (1907-2001), founded the Cancer Research Institute.

*Oliver R. Grace Award for Distinguished Service in Advancing Cancer Research
CRI’s Grace Award annually recognizes the contributions of dedicated laypersons whose leadership has had a significant impact on cancer research. The award is named in memory of Oliver R. Grace (1909-1992), the founding chairman of CRI, whose vision, leadership, wisdom, and generosity guided and continues to benefit the Institute.

*Frederick W. Alt Award for New Discoveries in Immunology
The Alt Award honors a former postdoctoral fellow in recognition of outstanding success in academia or industry for research that may have a potentially major impact on immunology. The award is named after CRI Scientific Advisory Council member Frederick W. Alt, Ph.D., who not only has made many seminal contributions to the field of immunology, but also has mentored generations of young scientists.

*AACR-CRI Lloyd J. Old Award in Cancer Immunology
Named in honor of CRI’s founding scientific and medical director, the AACR-CRI Lloyd J. Old Award in Cancer Immunology, funded in partnership with the American Association for Cancer Research, recognizes an active scientist whose outstanding and innovative research in cancer immunology has had a far-reaching impact on the cancer field.

*Helen Coley Nauts Service Award
This award honors individuals who have made significant contributions of time, energy, and service to CRI. The award is named in memory of CRI’s founder, Helen Coley Nauts, who dedicated her life to advancing immune system-based therapies for cancer.

Population(s) Served
Academics
Activists

Where we work

Accreditations

Better Business Bureau Wise Giving Alliance 2020

Charity Navigator 2020

Charity Watch 2020

Our results

SOURCE: Self-reported by organization

How does this organization measure their results? It's a hard question but an important one.

Total number of grants awarded

This metric is no longer tracked.
Totals By Year
Type of Metric

Output - describing our activities and reach

Direction of Success

Increasing

Context Notes

Includes CRI Irvington Postdoctoral Fellowships, Clinic and Laboratory Integration Program grants, Clinical Accelerator trial grants, Technology Impact Awards, designated funds, and annual awards.

Total dollar amount of grants awarded

This metric is no longer tracked.
Totals By Year
Type of Metric

Output - describing our activities and reach

Direction of Success

Increasing

Context Notes

Includes CRI Irvington Postdoctoral Fellowships, Clinic and Laboratory Integration Program grants, Clinical Accelerator trial grants, designated Impact Grants, and annual awards.

Number of unique website visitors

This metric is no longer tracked.
Totals By Year
Type of Metric

Output - describing our activities and reach

Direction of Success

Increasing

Context Notes

January 1 to December 31, 2019.

Our Sustainable Development Goals

SOURCE: Self-reported by organization

Learn more about Sustainable Development Goals.

Goals & Strategy

SOURCE: Self-reported by organization

Learn about the organization's key goals, strategies, capabilities, and progress.

Charting impact

Four powerful questions that require reflection about what really matters - results.

Over the next five years, the Cancer Research Institute will aim to:
(a) bring increasingly effective cancer immunotherapies to more cancer patient populations;
(b) expand awareness among patients, caregivers, and health care professionals of the power of cancer immunotherapy and its significant potential to slow or halt tumor growth, delay or prevent cancer recurrence, and extend patient lives, including members of underrepresented minority communities including Black, Hispanic and Latino/Latina, Asian American and Pacific Islander, and Indigenous populations;
(c) grow the general public's awareness of the revolution in cancer treatment and the need to continue funding critical research in order to optimize immunotherapy for more groups of cancer patients;

CRI will achieve its goals through:
(a) expanding the field's knowledge by funding laboratory research in immunology and tumor immunology at universities and medical centers around the globe;
(b) channeling new incremental funds into our translational and clinical research programs, which aim to test and optimize cancer immunotherapies;
(c) forging new collaborations with more pharmaceutical and biotech industry partners as well as nonprofit partners in order to gain access to highly promising immunotherapies and test them in our international clinical trials network;
(d) launching a new campaign targeting cancer patients and caregivers designed to educate these groups on cancer immunotherapy, connect them with one another to exchange experiences and knowledge, and motivate them to ask their oncologists about immunotherapy options when appropriate;
(e) growing our reach and impact in underrepresented communities of color including Black, Latino/Latina, Asian American, Pacific Islander, and Indigenous populations through (1) creation of funding opportunities for predoctoral students and young scientists from these communities interested in pursuing careers in immunology and tumor immunology; (2) translation of CRI's cancer immunotherapy information pages and resources into Spanish; (3) launch of an all Spanish-language Virtual Immunotherapy Patient Summit in Fall 2021 featuring Spanish-speaking immunotherapy experts and cancer patients and addressing health care disparities affecting this community.

The Cancer Research Institute is uniquely positioned to carry out the strategies above.
(a) Our longstanding postdoctoral fellowship program ensures a steady stream of intellectual talent to drive the field’s progress. Fellows ask fundamental questions about the immune system and its relationship to cancer, gaining new knowledge that fuels translational and clinical application.
(b) Through our Clinic and Laboratory Integration and Clinical Accelerator programs, we accelerate clinically-relevant discovery and optimization of immunotherapy in a wide variety of cancer types.
(d) As cancer immunotherapy enters the mainstream of treatment for more types of cancer, the need for trusted information about the available treatment options, how they work, and their potential side effects grows. Our website and offline events for patients and caregivers helps educate the public about this new approach to cancer treatment.

In the 68 years since CRI's founding, our scientists have made significant progress in advancing our understanding of the immune system and its response to cancer. This knowledge has resulted in game-changing treatments that harness the immune system's power to conquer cancer and save lives.

CRI scientists have laid a solid foundation of insights that have spurred the technological advances that make possible today's medical advances in cancer immunotherapy. The face of cancer treatment is changing, and the disease will soon become one that is manageable and in some cases curable rather than deadly.

As we look to the decade ahead, the Cancer Research Institute will continue to lead the field through its ability to establish unique, philanthropy-based partnerships between nonprofit and for-profit entities engaged in cancer immunotherapy research and development.

CRI will also continue to look for opportunities to address disparities in health equity for cancer patients from underrepresented minority communities and funding and training opportunities for individuals from these communities working to pursue careers as scientists in immunology and tumor immunology.

How we listen

SOURCE: Self-reported by organization

Seeking feedback from people served makes programs more responsive and effective. Here’s how this organization is listening.

done We demonstrated a willingness to learn more by reviewing resources about feedback practice.
done We shared information about our current feedback practices.
  • Who are the people you serve with your mission?

    Scientists, and cancer patients and caregivers.

  • How is your organization collecting feedback from the people you serve?

    Electronic surveys (by email, tablet, etc.), Community meetings/Town halls, Constituent (client or resident, etc.) advisory committees,

  • How is your organization using feedback from the people you serve?

    To identify bright spots and enhance positive service experiences, To inform the development of new programs/projects, To strengthen relationships with the people we serve,

  • With whom is the organization sharing feedback?

    Our staff, Our board,

  • Which of the following feedback practices does your organization routinely carry out?

  • What challenges does the organization face when collecting feedback?

Financials

Cancer Research Institute, Inc.
lock

Unlock financial insights by subscribing to our monthly plan.

Subscribe

Unlock nonprofit financial insights that will help you make more informed decisions. Try our monthly plan today.

  • Analyze a variety of pre-calculated financial metrics
  • Access beautifully interactive analysis and comparison tools
  • Compare nonprofit financials to similar organizations

Want to see how you can enhance your nonprofit research and unlock more insights?
Learn more about GuideStar Pro.

Operations

The people, governance practices, and partners that make the organization tick.

lock

Connect with nonprofit leaders

Subscribe

Build relationships with key people who manage and lead nonprofit organizations with GuideStar Pro. Try a low commitment monthly plan today.

  • Analyze a variety of pre-calculated financial metrics
  • Access beautifully interactive analysis and comparison tools
  • Compare nonprofit financials to similar organizations

Want to see how you can enhance your nonprofit research and unlock more insights? Learn More about GuideStar Pro.

lock

Connect with nonprofit leaders

Subscribe

Build relationships with key people who manage and lead nonprofit organizations with GuideStar Pro. Try a low commitment monthly plan today.

  • Analyze a variety of pre-calculated financial metrics
  • Access beautifully interactive analysis and comparison tools
  • Compare nonprofit financials to similar organizations

Want to see how you can enhance your nonprofit research and unlock more insights? Learn More about GuideStar Pro.

Cancer Research Institute, Inc.

Board of directors
as of 8/18/2021
SOURCE: Self-reported by organization
Board co-chair

Mr. Paul Shiverick

Seminole Capital Partners

Term: 2018 - 2022


Board co-chair

Mr. Andrew Tsai

Chalkstream Capital

Term: 2018 - 2022

Paul Shiverick

Seminole Capital Partners

Andrew Tsai

Chalkstream Capital

Edgar Berner

John Lang, Inc.

John Fitzgibbons

Basin Holdings

Donald Gogel

Clayton, Dubilier, & Rice LLC

Jacques Nordeman

Nordeman Grimm

Andrew Paul

Sopris Capital Associates

Geoffrey Coley

Mitsubishi UFJ Securities Holdings

Thomas Mendell

Donald Gogel

Clayton, Dubilier, & Rice LLC

John Fitzgibbons

Basin Holdings

Board leadership practices

SOURCE: Self-reported by organization

GuideStar worked with BoardSource, the national leader in nonprofit board leadership and governance, to create this section.

  • Board orientation and education
    Does the board conduct a formal orientation for new board members and require all board members to sign a written agreement regarding their roles, responsibilities, and expectations? Yes
  • CEO oversight
    Has the board conducted a formal, written assessment of the chief executive within the past year ? Yes
  • Ethics and transparency
    Have the board and senior staff reviewed the conflict-of-interest policy and completed and signed disclosure statements in the past year? Yes
  • Board composition
    Does the board ensure an inclusive board member recruitment process that results in diversity of thought and leadership? Not applicable
  • Board performance
    Has the board conducted a formal, written self-assessment of its performance within the past three years? Yes

Organizational demographics

SOURCE: Self-reported; last updated 04/12/2021

Who works and leads organizations that serve our diverse communities? GuideStar partnered on this section with CHANGE Philanthropy and Equity in the Center.

Leadership

The organization's leader identifies as:

Race & ethnicity
White/Caucasian/European
Gender identity
Female, Not transgender (cisgender)
Sexual orientation
Heterosexual or Straight
Disability status
Person without a disability

Race & ethnicity

Gender identity

 

Sexual orientation

Disability

No data

Equity strategies

Last updated: 04/12/2021

GuideStar partnered with Equity in the Center - an organization that works to shift mindsets, practices, and systems to increase racial equity - to create this section. Learn more

Data
  • We ask team members to identify racial disparities in their programs and / or portfolios.
  • We analyze disaggregated data and root causes of race disparities that impact the organization's programs, portfolios, and the populations served.
  • We disaggregate data to adjust programming goals to keep pace with changing needs of the communities we support.
  • We employ non-traditional ways of gathering feedback on programs and trainings, which may include interviews, roundtables, and external reviews with/by community stakeholders.
Policies and processes
  • We seek individuals from various race backgrounds for board and executive director/CEO positions within our organization.
  • We engage everyone, from the board to staff levels of the organization, in race equity work and ensure that individuals understand their roles in creating culture such that one’s race identity has no influence on how they fare within the organization.